VictorHugoG.Johnson (@vikouerMD) header
VictorHugoG.Johnson (@vikouerMD) profile picture

Attending Nephrologist @NefrologiaINC | Cardiorenal @geshNHS | Critical Care Nephrology @UAB_NRTC | POCUS | Music Lover | Calisthenics

Muddy Banks Of The Wishkah
Joined December 2009
Photo by VictorHugoG.Johnson (@vikouerMD)Photo by VictorHugoG.Johnson (@vikouerMD)Photo by VictorHugoG.Johnson (@vikouerMD)Photo by VictorHugoG.Johnson (@vikouerMD)Photo by VictorHugoG.Johnson (@vikouerMD)Photo by VictorHugoG.Johnson (@vikouerMD)Photo by VictorHugoG.Johnson (@vikouerMD)Photo by VictorHugoG.Johnson (@vikouerMD)Photo by VictorHugoG.Johnson (@vikouerMD)Photo by VictorHugoG.Johnson (@vikouerMD)
Un día en la mejor unidad de HDF del país Decidí explicar cómo es un día en la vida del residente de nefrología en la que yo (y muchos) consideran la mejor unidad de HDF. 🧵 🚨 🧵
6
11
1
69
VictorHugoG.Johnson retweeted
CRRT loses ~0.2 g of amino acids/L of effluent, or 10-15 g/day. IRRT loses ~12 g/session, and 5-10 g/day of protein may be lost. Water-soluble vitamins, selenium + copper are also at risk. 🎩 tip to the authors, including @SLCutuli @MarliesOst @emjsee eddyjoemd.com/foamed
1
65
167
6,447
VictorHugoG.Johnson retweeted
IV iron in #HFpEF : The #IRONMET-HFpEF Randomized Trial 📍 65 patients randomized to ferric derisomaltose 1000 mg IV vs placebo; 98.5% completed 12-week follow-up. 📍 Peak VO₂ improved significantly: +1.2 vs +0.1 mL/kg/min; LS mean difference +1.1 mL/kg/min (95% CI 0.2–1.9), P=0.02 📍 Functional gains: anaerobic-threshold VO₂, 6-minute walk distance, and NYHA class all improved vs placebo; KCCQ-OSS was not significantly different. 📌 Iron stores were effectively repleted with higher TSAT and ferritin, with no serious adverse events attributed to ferric derisomaltose ahajournals.org/doi/10.1161/… @AHAScience #ScientificSessions26 #AHA26 #HFpEF #HeartFailure #IronDeficiency @CircAHA
1
14
1
38
2,049
VictorHugoG.Johnson retweeted
Spironolactone is the workhorse diuretic for ascites. But it has side effects. Below I address the conversion to eplerenone. Now let’s try another: let’s say someone has uncontrolled ascites on 100mg of spiro. What dose and frequency of AMILORIDE would you use?
Replying to @ebtapper
1️⃣Eplerenone is weaker than spiro by ~50% (pmid 2949071). 2️⃣the doses used in CHF🫀 are low! and Epic will warn you that high doses are unsafe (unlike spiro). Scary! 3️⃣best to switch 1:1 or be prepared to rapidly increase 4️⃣eplero half life is 4-6 hours, BID may be necessary!
2
15
1
67
10,882
VictorHugoG.Johnson retweeted
🔴🔴Lp(a)HORIZON (@NEJM): pelacarsén 80 mg/mes bajó la Lp(a) de 236 a 64 nmol/L… y NO redujo eventos. MACE-4: 12,3 % vs 12,1 %; HR 1,02 (0,90–1,15) a 4,7 años. n = 8322 con ECV y Lp(a) ≥70 mg/dL. Bajar la Lp(a) no es lo mismo que bajar eventos. 🧵
3
20
49
3,437
VictorHugoG.Johnson retweeted
🫀Pharmacological treatment strategies to prevent #heartfailure across the cardiovascular-kidney-metabolic spectrum, an EJHF expert consensus statement: 📍Identify individuals at risk of developing HF: - Type 2 diabetes - Chronic kidney disease ± albuminuria - Hypertension and obesity - Atherosclerotic cardiovascular disease - Metabolic dysfunction-associated steatotic liver disease 📍Four foundational pharmacological strategies: 💊RAS inhibitors (ACEi/ARBs) 💊SGLT2 inhibitors 💊Non-steroidal MRAs (finerenone) 💊Incretin-based therapies (GLP-1 RAs and dual GLP-1/GIP agonists) 📍Early, accelerated treatment implementation: - Initiate complementary therapies early rather than delaying until clinical deterioration - Titrate rapidly and avoid unnecessary discontinuation - Individualize treatment according to clinical phenotype, risk, and tolerability 📍Structured monitoring and multidisciplinary care: - Laboratory monitoring at 1-4 weeks - Reintroduce therapies following temporary interruption when appropriate - Support nurse/pharmacist-led titration, digital monitoring, and patient education 📍Overcome implementation barriers: - Clinical inertia and polypharmacy - Renal safety concerns - Treatment costs and inequities - Fragmented healthcare delivery Read more in #EJHF @EJHFEiC : doi.org/10.1093/ejhf/xuag301 @escardio #HFA_ESC #HF #CKM
1
79
2
184
11,314
VictorHugoG.Johnson retweeted
IHD vs CRRT again. ICRAKI was stopped early due to higher mortality with IHD. Real signal or truncation artifact? And was IHD given the way we'd give it to a patient on vasopressors? #NephJC #nephtwitter ✍️ By @rn_flex @DivyaveerSSNeph nephjc.com/news/icraki11126
1
25
2
49
4,192
VictorHugoG.Johnson retweeted
3
7
35
2,074
VictorHugoG.Johnson retweeted
El deterioro de función renal observado al descongestionar con diuréticos no sería debido a la depleción de volumen, se explica mejor por los mecanismos intrarrenales que se originan. Aquí la compleja explicación Hypertension 2026 10.1161/HYPERTENSIONAHA.126.27712
66
1
226
7,998
Our research letter published in @EJIM_journal explores urinary calcium excretion as a potential biomarker of diuretic resistance in heart failure, presenting a hypothesis-generating study. ejinme.com/article/S0953-620…
1
8
1
14
661
VictorHugoG.Johnson retweeted
Los invitamos a participar en el 1er encuentro Cardiorrenal Iberoamericano con colaboración @SLANH_ @SENefrologia @IMINmx., en el marco de la #semanaIMIN. Tendremos contenido académico de gran nivel con profesores de LATAM y España. No se lo pierdan! @SLANHJoven @visanpolo
6
14
469
VictorHugoG.Johnson retweeted
#KidneyWk 2026 Round Up: Four articles were simultaneously published in NEJM and presented at this year’s American Society of Nephrology Meeting (@ASNKidney) in Denver.
1
19
72
34,467
🫀Finerenone vs spironolactone in heart failure with mildly reduced or preserved ejection fraction: a real-world study. see@ ow.ly/LcYk5100u04 @EJHFEiC @AmrAbdin10 @GiuseppeGalati_ @HanCardiomd @EJHFEiC @JanBiegus @ppponikowski #HFA_ESC @hvanspall @FudimMarat @gcfmd @MarcoMetra @GianluSava #ESCHeartFailure
3
142
8
413
37,569
VictorHugoG.Johnson retweeted
GDMT is Associated with Reduced Loop Diuretic Requirements, Whereas Diuretic Dose Does Not Modify GDMT Benefit in Heart Failure: STRONG-HF. GDMT optimization acted as diuretic-sparing therapy: reaching target doses, particularly of all three classes, was associated with markedly lower LD requirement. @hfcollaboratory @gcfmd @SJGreene_md @mvaduganathan academic.oup.com/eurjhf/adva…
1
4
23
799
VictorHugoG.Johnson retweeted
Management of Heart Failure With Preserved Ejection Fraction: 2026 ACC Expert Consensus Decision Pathway: A Report of the American College of Cardiology Solution Set Oversight Committee HFpEF: beyond EF! ACC 2026: • SGLT2i ± finerenone if eligible • Incretins for obesity • Diuretics for congestion • ARNI by phenotype • No routine beta-blockers without a specific indication Tailor care to phenotype and sex. #HFpEF #CardioTwitter @mvaduganathan @gcfmd @SJGreene_md @JavedButler1 @BiykemB jacc.org/doi/10.1016/j.jacc.…
38
139
4,531
VictorHugoG.Johnson retweeted
📢 1-Y outcomes in 🇪🇸CardioRen 🔹 Kidney Function was associated with ⬆️events 🔹 Event rates were ⬇️than historical cohorts. 🔹 eGFR predicted mortality, but not the composite outcome. 🔹 Congestion and comorbidities ➡️key drivers of morbidity. revespcardiol.org/en-prognos…
2
25
50
2,313
VictorHugoG.Johnson retweeted
Monitoring and dose adjustment of regional citrate anticoagulation for continuous renal replacement therapy CCR Journal Watch criticalcarereviews.com/late…
54
176
8,743
VictorHugoG.Johnson retweeted
Following a recommendation from the DMD Boehringer Ingelheim has decided to discontinue the EASi-KIDNEY trial (NCT06531824) Testing vicadrostat (BI 690517), in combination with empagliflozin vs empagliflozin alone, could slow CKD and ⬇️ CV events boehringer-ingelheim.com/hum…
14
5
33
34,119
VictorHugoG.Johnson retweeted
Simplemente no hay evidencia para prescribir espironolactona en personas en diálisis, aquí los ensayos clínicos que no demostraron beneficio: •SPin-D❌ •MiREnDa❌ Y con más detalle👇🏻 •ALCHEMIST ❌ •ACHIEVE ❌ AJKD 2026 10.1053/j.ajkd.2026.04.020
42
1
149
7,425
VictorHugoG.Johnson retweeted
‘26 HF RCTs HFpEF GLP1: #MARITIME #HFPolaris #ELEVATE sMRA: #SPIRRIT nsMRA: #REDEFINE ASi: #EASiHFPres CMI: #AURORA #AMBER #EQUINOX HFrEF GLP1: #Enith nsMRA: #FINALITY ASi: #EASiHFRed Myosin Act: #COMET Colchicine: #COLHEF IV Fe: #ICONIC All LVEF nsMRA: #BalanceD #CONFIRMATION
2
31
117
10,979